TY  - JOUR

T1  - 12-month effectiveness and tolerability of brivaracetam in the real-world: interim analysis of the international, non-interventional EXPERIENCE study (P13-8.002)

JO  - Neurology

UR  - http://dx.doi.org/10.1212/wnl.98.18_supplement.1407

PY  - 2022/05/03

AU  - Villanueva V

AU  - D’Souza W

AU  - Faught E

AU  - Klein P

AU  - Reuber M

AU  - Rosenow F

AU  - Salas-Puig J

AU  - Strzelczyk A

AU  - Szaflarski J

AU  - Ricchetti-Masterson K

AU  - Laloyaux C et al

ED  - 

DO  - DOI: 10.1212/wnl.98.18_supplement.1407

PB  - Ovid Technologies (Wolters Kluwer Health)

VL  - 98

IS  - 18_supplement

Y2  - 2024/12/22

ER  -